Zai Lab FY2026 EPS Forecast Lowered by Leerink Partnrs

Key Points

• Leerink Partners has lowered its FY2026 earnings forecast for Zai Lab, now predicting an EPS of $0.45, down from $0.51, while the consensus estimate stands at a loss of $2.58 per share.
• Zai Lab's recent quarterly earnings resulted in a loss of ($0.37) per share, matching expectations, but revenues fell short of estimates at $109.98 million compared to $125.66 million.
• The stock has recently been received mixed ratings, with a consensus of "Moderate Buy" based on multiple analysts' target prices ranging from $52.00 to $75.00.

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Free Report) - Equities researchers at Leerink Partnrs dropped their FY2026 earnings estimates for shares of Zai Lab in a note issued to investors on Thursday, September 4th. Leerink Partnrs analyst J. Chang now expects that the company will post earnings per share of $0.45 for the year, down from their previous forecast of $0.51. The consensus estimate for Zai Lab's current full-year earnings is ($2.58) per share.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.37) earnings per share for the quarter, hitting the consensus estimate of ($0.37). The company had revenue of $109.98 million for the quarter, compared to analyst estimates of $125.66 million. Zai Lab had a negative net margin of 49.68% and a negative return on equity of 27.32%. Zai Lab has set its FY 2025 guidance at EPS.

ZLAB has been the subject of a number of other reports. Citigroup reissued a "buy" rating and issued a $69.00 target price (up from $66.00) on shares of Zai Lab in a research note on Monday, August 11th. Jefferies Financial Group assumed coverage on Zai Lab in a research report on Monday, August 25th. They issued a "buy" rating and a $52.00 price objective for the company. Leerink Partners set a $75.00 target price on Zai Lab and gave the stock an "outperform" rating in a research note on Monday, June 30th. Finally, Wall Street Zen downgraded shares of Zai Lab from a "buy" rating to a "hold" rating in a report on Friday, June 27th. Six analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, Zai Lab has a consensus rating of "Moderate Buy" and an average price target of $56.35.

Zai Lab Stock Up 2.5%

ZLAB opened at $30.76 on Monday. The stock has a market cap of $3.44 billion, a P/E ratio of -15.08 and a beta of 1.04. Zai Lab has a 12 month low of $19.16 and a 12 month high of $44.34. The company has a fifty day simple moving average of $35.22 and a 200 day simple moving average of $34.09.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Principal Financial Group Inc. raised its stake in shares of Zai Lab by 63.6% during the 1st quarter. Principal Financial Group Inc. now owns 2,884,810 shares of the company's stock worth $104,257,000 after purchasing an additional 1,121,856 shares in the last quarter. RTW Investments LP acquired a new position in Zai Lab during the fourth quarter worth $65,714,000. Mirae Asset Global Investments Co. Ltd. raised its position in Zai Lab by 46,222.0% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,132,201 shares of the company's stock worth $77,058,000 after acquiring an additional 2,127,598 shares in the last quarter. Allianz Asset Management GmbH raised its position in Zai Lab by 25.1% during the first quarter. Allianz Asset Management GmbH now owns 1,884,411 shares of the company's stock worth $68,103,000 after acquiring an additional 378,545 shares in the last quarter. Finally, Woodline Partners LP lifted its stake in Zai Lab by 9.4% in the fourth quarter. Woodline Partners LP now owns 1,759,797 shares of the company's stock valued at $46,089,000 after acquiring an additional 151,835 shares during the last quarter. Institutional investors and hedge funds own 41.65% of the company's stock.

Insider Activity

In other news, CEO Ying Du sold 50,000 shares of the firm's stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $34.74, for a total transaction of $1,737,000.00. Following the completion of the transaction, the chief executive officer directly owned 536,962 shares of the company's stock, valued at $18,654,059.88. This trade represents a 8.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Rafael Amado sold 3,000 shares of the business's stock in a transaction on Friday, August 8th. The stock was sold at an average price of $35.00, for a total transaction of $105,000.00. Following the completion of the sale, the insider directly owned 42,178 shares in the company, valued at approximately $1,476,230. This represents a 6.64% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 215,710 shares of company stock worth $7,589,684. 4.96% of the stock is currently owned by insiders.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.